CO-AMP-ROBOTICS-CORP
19.7.2021 10:02:11 CEST | Business Wire | Press release
AMP Robotics Corp. (“AMP”), a pioneer in AI, robotics, and infrastructure for the waste and recycling industry, is expanding its presence in Europe as demand grows for the company’s AI and automation solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210719005207/en/
AMP has appointed REP-TEC Advanced Technologies , specialists in the supply, installation, and support of recycling equipment, as an official reseller and integrator for customers in the United Kingdom and Ireland. In addition, to further support the expansion of its business in Europe, AMP has hired Gary Ashburner as its European General Manager to build out the company’s infrastructure across the region. Based in the UK, Ashburner leads customer and partner acquisition, pre- and post-sales consulting, system design, supply, installation, training, and service.
“We’re seeing greater interest in and adoption of our technology in the U.S., with customers reordering our AI-guided robotic sorting systems to install in other facilities that they own. This is generating a robust pipeline in the U.S. that’s being mirrored internationally, following the installation of our first robotic sorting system in Europe late last year,” said Ashburner. “We share a commitment to improving global resource efficiency and productivity with REP-TEC, and look forward to working with an established leader that also embraces new technology and innovation as we extend our efforts to modernize and expand recycling infrastructure in Europe and globally.”
AMP’s European expansion reflects strong year-over-year revenue growth and investment in operational scale made possible by its latest funding round of USD $55 million at the beginning of the year. The company’s AI platform, AMP Neuron™, encompasses the largest known real-world dataset of recyclable materials for machine learning , with the ability to classify more than 100 different categories and characteristics of recyclables across single-stream recycling, e-scrap, and construction and demolition debris, and reaching an object recognition run rate of more than 10 billion items annually.
“We’re delighted to partner with AMP Robotics and support the company’s growth across the UK and Ireland,” said Colm Grimes, CEO of REP-TEC. “We recognize the desire to add AI and robotics to Europe’s recycling infrastructure and believe AMP has developed a system that will change the economics of this industry. We’ll be installing our first three AMP Cortex™ high-speed sorting systems later this summer. This will provide a great UK reference site with the ability to run material trials for interested parties.”
To further its market penetration, AMP is actively seeking to establish additional reseller partnerships in Belgium, The Netherlands, Luxembourg, Germany, and France.
About AMP Robotics™ Corp.
AMP Robotics is modernizing the world’s recycling infrastructure by applying AI and automation to increase recycling rates and economically recover recyclables reclaimed as raw materials for the global supply chain. The AMP Cortex™ high-speed robotics system automates the identification and sorting of recyclables from mixed material streams. The AMP Neuron™ AI platform continuously trains itself by recognizing different colors, textures, shapes, sizes, patterns, and even brand labels to identify materials and their recyclability. Neuron then guides robots to pick and place the material to be recycled. Designed to run 24/7, all of this happens at superhuman speed with extremely high accuracy. AMP Clarity™ provides data and material characterization on what recyclables are captured and missed, helping recycling businesses and producers maximize recovery. With deployments across North America, Asia, and Europe, AMP’s technology recovers recyclables from municipal collection, precious commodities from electronic scrap, and high-value materials from construction and demolition debris.
About REP-TEC
REP-TEC was formed with a vision to improve global resource efficiency through automation and harnessing new waste recycling technologies. REP-TEC are specialists in the design, manufacture, installation, and support of a range of recycling solutions. The REP-TEC portfolio includes fully automatic balers, conveyor systems, compactors, and the AMP Cortex™ high-speed robotics systems. REP-TEC is passionate about innovation and exploring clients’ workstreams to uncover opportunities for significant efficiency improvements. With coverage throughout the UK and Ireland, REP-TEC provides nationwide aftersales service and support that meets the most demanding Service Level Agreements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210719005207/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom